These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study. Chu TQ; Ding H; Garfield DH; Gu AQ; Pei J; Du WD; Han BH J Thorac Oncol; 2012 Dec; 7(12):1781-1789. PubMed ID: 23154549 [TBL] [Abstract][Full Text] [Related]
8. Invited commentary. Lim E Ann Thorac Surg; 2007 Jan; 83(1):202-3. PubMed ID: 17184662 [No Abstract] [Full Text] [Related]
9. MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer. Li W; Wang Y; Zhang Q; Tang L; Liu X; Dai Y; Xiao L; Huang S; Chen L; Guo Z; Lu J; Yuan K PLoS One; 2015; 10(8):e0134220. PubMed ID: 26237047 [TBL] [Abstract][Full Text] [Related]
10. COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Shen L; Yang M; Lin Q; Zhang Z; Zhu B; Miao C Oncol Rep; 2016 Aug; 36(2):877-85. PubMed ID: 27373316 [TBL] [Abstract][Full Text] [Related]
12. Validation of a reverse transcription-polymerase chain reaction-based five-gene signature in non-small cell lung cancer. Ruco L; Scarpino S; Natoli G J Thorac Oncol; 2009 May; 4(5):670. PubMed ID: 19395916 [No Abstract] [Full Text] [Related]
13. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer. Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761 [TBL] [Abstract][Full Text] [Related]
14. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer. Kanaoka R; Iinuma H; Dejima H; Sakai T; Uehara H; Matsutani N; Kawamura M Oncology; 2018; 94(5):311-323. PubMed ID: 29533963 [TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of CUG-binding protein 1 expression and vascular invasion after radical surgery for stage IB nonsmall cell lung cancer. Zhao J; Zhao Y; Xuan Y; Jiao W; Qiu T; Wang Z; Luo Y Indian J Cancer; 2015 Dec; 52 Suppl 2():e125-9. PubMed ID: 26728670 [TBL] [Abstract][Full Text] [Related]
18. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer. Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880 [TBL] [Abstract][Full Text] [Related]
19. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer. Igawa S; Sato Y; Ishihara M; Kasajima M; Kusuhara S; Nakahara Y; Otani S; Fukui T; Katagiri M; Sasaki J; Masuda N Asian Pac J Cancer Prev; 2016; 17(7):3249-53. PubMed ID: 27509958 [TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms and non-small-cell lung cancer: future paradigms. de Mello RA Einstein (Sao Paulo); 2014; 12(4):524-6. PubMed ID: 25628210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]